JP2022544272A5 - - Google Patents

Info

Publication number
JP2022544272A5
JP2022544272A5 JP2022508779A JP2022508779A JP2022544272A5 JP 2022544272 A5 JP2022544272 A5 JP 2022544272A5 JP 2022508779 A JP2022508779 A JP 2022508779A JP 2022508779 A JP2022508779 A JP 2022508779A JP 2022544272 A5 JP2022544272 A5 JP 2022544272A5
Authority
JP
Japan
Prior art keywords
diffraction pattern
ray powder
powder diffraction
pattern containing
fumarate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022508779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544272A (ja
JP7775186B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/045847 external-priority patent/WO2021030386A1/en
Publication of JP2022544272A publication Critical patent/JP2022544272A/ja
Publication of JP2022544272A5 publication Critical patent/JP2022544272A5/ja
Priority to JP2025113638A priority Critical patent/JP2025148406A/ja
Application granted granted Critical
Publication of JP7775186B2 publication Critical patent/JP7775186B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022508779A 2019-08-13 2020-08-12 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態 Active JP7775186B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025113638A JP2025148406A (ja) 2019-08-13 2025-07-04 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962885977P 2019-08-13 2019-08-13
US62/885,977 2019-08-13
PCT/US2020/045847 WO2021030386A1 (en) 2019-08-13 2020-08-12 Salt and crystal forms of an activin receptor-like kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025113638A Division JP2025148406A (ja) 2019-08-13 2025-07-04 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態

Publications (3)

Publication Number Publication Date
JP2022544272A JP2022544272A (ja) 2022-10-17
JP2022544272A5 true JP2022544272A5 (cg-RX-API-DMAC10.html) 2023-08-21
JP7775186B2 JP7775186B2 (ja) 2025-11-25

Family

ID=72193669

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022508779A Active JP7775186B2 (ja) 2019-08-13 2020-08-12 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態
JP2025113638A Pending JP2025148406A (ja) 2019-08-13 2025-07-04 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025113638A Pending JP2025148406A (ja) 2019-08-13 2025-07-04 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態

Country Status (15)

Country Link
US (1) US20220281879A1 (cg-RX-API-DMAC10.html)
EP (1) EP4013757A1 (cg-RX-API-DMAC10.html)
JP (2) JP7775186B2 (cg-RX-API-DMAC10.html)
KR (1) KR102967623B1 (cg-RX-API-DMAC10.html)
CN (2) CN114222745B (cg-RX-API-DMAC10.html)
AU (1) AU2020328534B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022002597A2 (cg-RX-API-DMAC10.html)
CA (1) CA3146701A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022001450A2 (cg-RX-API-DMAC10.html)
IL (1) IL290482A (cg-RX-API-DMAC10.html)
JO (1) JOP20220014A1 (cg-RX-API-DMAC10.html)
MX (2) MX2022001741A (cg-RX-API-DMAC10.html)
TW (1) TWI870440B (cg-RX-API-DMAC10.html)
UA (1) UA130650C2 (cg-RX-API-DMAC10.html)
WO (1) WO2021030386A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3442977T3 (fi) * 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
CA3117695A1 (en) 2018-10-26 2020-04-30 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2026161341A1 (en) * 2025-01-21 2026-07-30 Blueprint Medicines Corporation Drug product formulations of fidrisertib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3442977T3 (fi) * 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol

Similar Documents

Publication Publication Date Title
JP6966590B2 (ja) オメカムチブメカルビルの塩及び塩を調製するプロセス
DK2498610T3 (en) Selective sphingosine-1-phosphate receptor modulators and methods of chiral synthesis
AU2012201453C1 (en) Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP2041093B1 (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
JP6832946B2 (ja) キナーゼ阻害剤およびその中間体の調製方法
JP2005503386A5 (cg-RX-API-DMAC10.html)
BG107510A (bg) Карбоксамидни съединения и тяхното използване като антагонисти на човешки 11 cby рецептор
JP2013541592A5 (cg-RX-API-DMAC10.html)
JP2022551525A5 (cg-RX-API-DMAC10.html)
EP2619190B1 (en) Substituted oxadiazole compounds and their use as s1p1 agonists
EP3089976A1 (en) Crystalline forms of afatinib di-maleate
EP2707364B1 (en) Process for the manufacture of dabigatran etexilate and intermediates thereof
JP2024521412A5 (cg-RX-API-DMAC10.html)
JP2022523368A5 (cg-RX-API-DMAC10.html)
CN101448819A (zh) (5s)-5-[4-(5-氯-吡啶-2-基氧基)-哌啶-1-磺酰基甲基]-5-甲基-咪唑烷-2,4-二酮的新晶体变化形式及其中间体
JP2024505063A5 (cg-RX-API-DMAC10.html)
JP2025131810A (ja) タンパク質キナーゼ阻害剤としてのヘテロ環化合物の結晶形
JP2024523506A5 (cg-RX-API-DMAC10.html)
TWI374136B (en) Water adduct of acetamide moohydrochloride and its crystal
JP2018522945A5 (cg-RX-API-DMAC10.html)
CN1104435C (zh) N-[(1-正丁基-4-哌啶基)甲基]-3,4-二氢-2H-[1,3] 噁嗪并[3,2-α]吲哚-10-甲酰胺及其盐的制备方法及在本方法中的中间体的制备方法
JP2024529533A5 (cg-RX-API-DMAC10.html)
CN102333762A (zh) 乙胺类化合物及其在治疗抑郁症中的用途
RU2022103256A (ru) Соль и кристаллические формы ингибитора активин-рецептороподобной киназы
CN102300851A (zh) 制备含羧基的吡唑酰氨基化合物597的新方法